Elevated expression of ribosomal protein genes L37, RPP-1, and S2 in the presence of mutant p53.
The wild-type p53 protein is a DNA-binding transcription factor that activates genes such as p21, MDM2, GADD45, and Bax that are required for the regulation of cell cycle progression or apoptosis in response to DNA damage. Mutant forms of p53, which are transforming oncogenes and are expressed at high levels in tumor cells, generally have a reduced binding affinity for the consensus DNA sequence. Interestingly, some p53 mutants that are no longer effective at binding to the consensus DNA sequence and transactivating promoters containing this target site have acquired the ability to transform cells in culture, in part through their ability to transactivate promoters of a number of genes that are not targets of the wild-type protein. Certain p53 mutants are therefore considered to be gain-of-function mutants and appear to be promoting proliferation or transforming cells through their ability to alter the expression of novel sets of genes. Our goal is to identify genes that have altered expression in the presence of a specific mutant p53 (Arg to Trp mutation at codon 248) protein. Through examining differential gene expression in cells devoid of p53 expression and in cells that express high levels of mutant p53 protein, we have identified three ribosomal protein genes that have elevated expression in response to mutant p53. Consistent with these findings, the overexpression of a number of ribosomal protein genes in human tumors and evidence for their contribution to oncogenic transformation have been reported previously, although the mechanism leading to this overexpression has remained elusive. We show results that indicate that expression of these specific ribosomal protein genes is increased in the presence of the R248W p53 mutant, which provides a mechanism for their overexpression in human tumors.
Loging
W T
WT
Department of Biological Sciences, University of South Carolina, Columbia 29208, USA.
Reisman
D
D
D000818:Animals; D015152:Blotting, Northern; D015153:Blotting, Western; D003110:Colonic Neoplasms / Q000235:genetics*; D018076:DNA, Complementary / Q000302:isolation & purification; D015972:Gene Expression Regulation, Neoplastic; D016158:Genes, p53; D006801:Humans; D017403:In Situ Hybridization; D051379:Mice; D010446:Peptide Fragments / Q000032:analysis / Q000235:genetics; D017354:Point Mutation; D012269:Ribosomal Proteins / Q000235:genetics*; D012680:Sensitivity and Specificity; D014407:Tumor Cells, Cultured; D016159:Tumor Suppressor Protein p53 / Q000235:genetics*
D018076:DNA, Complementary; D010446:Peptide Fragments; C488984:RPL37 protein, human; D012269:Ribosomal Proteins; D016159:Tumor Suppressor Protein p53; C030004:ribosomal protein S2